A ruling by the Supreme Court made on the second to last day of its term will have major implications for Planned Parenthood. The court ruled for South Carolina yesterday in its effort to defund the reproductive health care group, concluding Medicaid patients cannot sue the state over its attempt to deny Planned Parenthood Medicaid funding. The ruling was along ideological lines with all six conservative justices backing the decision and the three liberal judges opposing it.Let's bring in senior Supreme Cou ...

ORLANDO, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the fourth quarter ended September 30, 2024 of $20.9 was relatively unchanged from the quarter ended September 30, 2023. Gross profit as a percentage of net revenue was 25.6% for the quarter ended September 30, 2024, compared to 31.7% for the quarter ended September 30, 2023. The higher gross profit margin in fiscal 2023 was due to increased parts sales a ...

Harvard and other top universities look to big tech and pharma companies to fill federal funding gap after Trump cuts https://t.co/jd9YSm8cqY ...

Today, the conservative majority on the United States Supreme Court ruled that states can effectively defund Planned Parenthood, the country's largest provider of reproductive health care. In a 63 ruling, the court changed federal law allowing states to unilaterally cut off all Medicaid funding from Planned Parenthood simply on the basis that it provides abortion care. Now, to be clear, abortion makes up only 3%. Abortion care only makes up 3% of Planned Parenthood services.It is a crucial 3% but it's 3%. T ...

LAS VEGAS, June 26, 2025 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), Transforming the Landscape of Social Commerce, Social Telehealth and Social Crowdfunding with MARKET.live; VANITYPrescribed; GoodGirlRx; and the GO FUND YOURSELF TV Show, today announced its MARKET.live division will produce and host a high-profile Walmart livestream shopping event for gut-health brand BelliWelli. The exclusive livestream will air on Walmart.com on Tuesday, July 1, 2025, at 4 ...

RT Ivan 🧳 (@ivan_nomadz)The smartest pre-seed builders aren't chasing VCs. They're leveraging grants.Solana's ecosystem offers some of the most founder-friendly funding available - non-dilutive capital that lets you build without giving up equity or control.Here are 7 active Solana grant programs you can apply to right now:🔹 Solana Foundation@SolanaFndn is supporting ecosystem growth through strategic funding for developers, researchers, and validators building core infrastructure and public goods.🔹 Superte ...

Core Viewpoint - Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501), a metronidazole oral suspension, and is actively pursuing funding opportunities to support its development programs and enhance its market position [2][3][14]. Group 1: Product Development and Market Position - LIKMEZ™ (ATI-1501) is the first FDA-approved, ready-to-use liquid oral suspension of metronidazole, specifically designed for patients who have difficulty swallowing tablets or are sensitive to taste [3][4]. - The re-launch of LIKMEZ follows new patent coverage extending to 2039, marking a significant milestone for the company and its partner, Saptalis Pharmaceuticals [2]. - Appili is focused on driving continued sales of LIKMEZ while advancing other product candidates, including ATI-1701 and ATI-1801 [3]. Group 2: Funding and Financial Performance - The company has submitted five non-dilutive funding proposals to the U.S. government, with a total potential value of up to US$125 million, aimed at supporting the development of critical infectious disease products [3][14]. - For the fiscal year ended March 31, 2025, Appili reported a net loss of CAD 2.6 million, which is an improvement from a net loss of CAD 3.8 million in the previous year, primarily due to increased government assistance and other income [19][20]. - As of March 31, 2025, the company had cash reserves of CAD 1.2 million, a significant increase from CAD 0.1 million a year earlier, indicating improved liquidity [21]. Group 3: Research and Development Progress - ATI-1701, a biodefense vaccine candidate for tularemia, has received approximately US$11.6 million in funding from the U.S. Air Force Academy and has shown promising results in providing protection against lethal tularemia [5][6]. - The company is actively pursuing additional funding and partnership opportunities for ATI-1801, a topical antiparasitic product that has received Orphan Drug Designation from the FDA [10][13]. - Appili has successfully completed technology transfer for the ATI-1701 manufacturing process, supporting future development activities [8].

REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has partnered with Royalty Pharma on $2 billion in flexible funding to support Revolution Medicines' independent global development and commercialization strategy and operations. Revolution Medicines retains full strategic and executional control of product development and commer ...

The next industrial revolution isn't being powered by coal or oil. This time, the most valuable resource is artificial intelligence. And while Silicon Valley often steals the headlines, Europe certainly isn't out of the race.From London to Leyon, Munich to Milan, a new generation of AI startups is emerging. But the money and the scale is often smaller. Last year, America's AI companies secured more than seven times the funding of their European rivals, and patents related to AI in the US outnumber those fro ...

Just out of the corner of my eye, I see a couple of massive rockets which dominate the skyline here. Why doesn't Europe and its space industry dominate in the same way that that we see in the United States. What is it that we're not doing here, not funding here that we need to fund to be on par.I mean, I wouldn't say that Europe is not dominating. We have some of the programs that are the world's best programs that day. Earth Observation, the Copernicus program is delivering the largest amounts of data of o ...